Halozyme Therapeutics Inc is a pharmaceutical company based in the United States, specializing in the development and commercialization of innovative oncology therapies. With a low ESG risk rating score of 19.9, Halozyme focuses on utilizing human enzymes to target and modify tumors. The company prioritizes creating treatments for unmet medical needs, particularly in the oncology field. Halozyme also collaborates with biopharmaceutical companies to license its technology for product development. Operating primarily in the US, Halozyme has minimal international assets.